Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor‐2 (VEGFR2) has been established as a therapeutic strategy for treating cancer. However, because of their low selectivity, most small molecule inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chengying, Wan, Xiaozhe, Quan, Haitian, Zheng, Mingyue, Fu, Li, Li, Yun, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891194/
https://www.ncbi.nlm.nih.gov/pubmed/29446853
http://dx.doi.org/10.1111/cas.13536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891194/
https://www.ncbi.nlm.nih.gov/pubmed/29446853
http://dx.doi.org/10.1111/cas.13536

Ejemplares similares